Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis

Abstract

Alnuctamab, a B‐cell maturation antigen (BCMA)‐targeting T‐cell engager, has demonstrated encouraging antitumor activity in the phase I study CC‐93269‐MM‐001 treating patients with relapsed or refractory multiple myeloma. Identification of a recommended Phase III dose (RP3D) was a key objective, as such population pharmacokinetic (PopPK) and exposure–response analysis was critical. Intravenous (IV) alnuctamab was administered in fixed doses (0.15–10 mg) or in step‐up doses to a maximum 10‐mg target dose. Subcutaneous (SC) step‐up doses of 3 and 6 mg were followed by a target dose range of 10–60 mg. Concentration data from IV and SC alnuctamab administration was pooled and was well described by a two‐compartment PopPK model with first‐order absorption and elimination. Covariate analysis determined that the inclusion of baseline soluble BCMA (sBCMA) on clearance significantly improved model fitting. Individual exposure parameters were estimated from the final model to characterize exposure–response relationships. Switching from IV to SC administration improved the safety profile of alnuctamab by limiting the frequency of grade ≥2 CRS events. A significant exposure–CRS relationship was observed after the first SC dose, but not subsequent dose administrations. Exposure–safety analysis did not find a statistically significant relationship between increasing exposure and the probability of key safety events of interest. Logistic regression analysis for patients administered SC alnuctamab identified that increased exposure significantly increased the probability of response, although the additional benefit was minimal at exposures above 30 mg target dose. Considering the totality of exposure–response data, the clinical pharmacology assessment supported a SC RP3D of 3/6/30 mg.